Ethosuximide NDC 42806-711

NDC codes

FDA NDC Directory

Product NDC (as listed)42806-711Labeler and product segments. Claims need a package NDC.

Product NDC at billing width42806-0711Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
42806-711-01	42806071101	100 CAPSULE in 1 BOTTLE (42806-711-01)Marketed from Apr 15, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ethosuximide
Generic name (nonproprietary): ethosuximide
Active ingredients: Ethosuximide — 250 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Epic Pharma, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210654
Marketing start: Mar 16, 2020
Listing expires: Dec 31, 2026
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 42806-711_2b366128-2db7-bb4e-e063-6294a90af2d7SPL ID 2b366128-2db7-bb4e-e063-6294a90af2d7SPL set ID a040dab2-0d70-4c02-a830-5ba1e3506a1bRxCUI 197682UNII 5SEH9X1D1D
Pharmacologic class: Anti-epileptic Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N442806071101 followed by a unit qualifier and the quantity

Package 42806-0711-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 8, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Ethosuximide is indicated for the control of absence (petit mal) epilepsy.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 210654

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 210654
Product	Strength	Form · route	Labeler	Product NDC
Ethosuximide	Ethosuximide 250 mg/1	CapsuleOral	Epic Pharma, LLC	42806-708